Advertisement

Corrigendum to ‘Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients [European Journal of Cancer 163 (2022) 128–139]

  • Maria M. Karsten
    Correspondence
    Corresponding author: Charite´ e Universitätsmedizin Berlin, Klinik fü r Gyna¨kologie mit Brustzentrum, Charite´platz 1 Berlin, D e 10117, Germany.
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Gynecology with Breast Center, Berlin, Germany
    Search for articles by this author
  • Robert Roehle
    Affiliations
    Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany
    Search for articles by this author
  • Sarah Albers
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Gynecology with Breast Center, Berlin, Germany
    Search for articles by this author
  • Therese Pross
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Gynecology with Breast Center, Berlin, Germany
    Search for articles by this author
  • Anna M. Hage
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Gynecology with Breast Center, Berlin, Germany
    Search for articles by this author
  • Karoline Weiler
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Gynecology with Breast Center, Berlin, Germany

    Klinikum Dritter Orden, Munich, Germany
    Search for articles by this author
  • Felix Fischer
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Berlin, Germany
    Search for articles by this author
  • Matthias Rose
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Berlin, Germany
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally.
    Friedrich Kühn
    Footnotes
    1 These authors contributed equally.
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Gynecology with Breast Center, Berlin, Germany
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally.
    Jens-Uwe Blohmer
    Footnotes
    1 These authors contributed equally.
    Affiliations
    Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Gynecology with Breast Center, Berlin, Germany
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally.
Open AccessPublished:August 12, 2022DOI:https://doi.org/10.1016/j.ejca.2022.06.052
      The authors regret that values of the cognitive functioning scale of the EORTC QLQ-C30 in patients with breast diseases at baseline have been recalculated since the publication of this article. All other scores of the EORTC QLQ-C30 were reported correctly in the previous publication.
      The mean CF scores were higher than previously reported with values between approx. 82 and 86 (Table 2). These values are much closer to the norm data of the German general population (mean 85.4). Median CF scores of breast cancer patients were lower by 17 points compared to fibroadenoma patients and patients with other breast diseases.
      Also, the relative frequency of patients below the threshold of clinical significance (= 75) was indeed lower than previously reported (227/729 (31%)). Figure 2 was corrected accordingly showing a distribution much more in line with the other scales.
      CF was found to be better in patients with fibroadenoma (0.23; 95% CI (−0.05)–0.51; p = 0.1040) and other breast diseases (0.42; 95% CI 0.20–0.65; p = 0.0002) than in patients with breast cancer. Due to the now non-normal distribution of the values, a beta regression model was implemented. Older (estimate per 10 year increase 0.08; 95% CI 0.00–0.16; p = 0.0374) and married persons showed an increased CF (0.28; 95% CI 0.06–0.50; p = 0.0139). In contrast, patients with neurological disorders (−0.86; 95% CI -1.31 to −0.42; p = 0.0001), depression (−1.02; 95% CI -1.29 to −0.75; p < 0.0001), previous surgery (−0.24; 95% CI -0.44 to −0.03; p = 0.0223) showed a reduced CF (Table 3).
      In conclusion, the difference in cognitive functioning in breast cancer patients at baseline compared to patients with benign breast diseases is less pronounced than previously reported.
      The authors would like to apologise for any inconvenience caused.

      Linked Article